Healthcare Wrap: Biotron and Cyclopharm Surge as FDA and Guideline Wins Drive Buyers
1:08pm on Saturday 31st of January, 2026 AEDT
Key Points
Biotron (ASX:BIT) jumped <span class="text-success"><i class="ci-trending-up me-1"></i>33.33%</span> after funding and deal progress around its hepatitis B and Sedarex assets
Cyclopharm (ASX:CYC) rose <span class="text-success"><i class="ci-trending-up me-1"></i>32.95%</span> as Technegas gained support in a key US lung imaging guideline and the company pushed into COPD research
4DMedical (ASX:4DX) slid <span class="text-danger"><i class="ci-trending-down me-1"></i>-21.73%</span> even as US hospital adoption continued, showing investors still want clearer revenue visibility
Across the sector, FDA clearances and Medicare billing changes kept rewarding companies closest to real sales